{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T02:06:38Z","timestamp":1790474798070,"version":"4.1.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,5,6]],"date-time":"2019-05-06T00:00:00Z","timestamp":1557100800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,5,6]],"date-time":"2019-05-06T00:00:00Z","timestamp":1557100800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Limb-girdle muscular dystrophy type 2D (LGMD2D) is characterized by a progressive proximal muscle weakness. LGMD2D is caused by mutations in the gene encoding \u03b1-sarcoglycan (\u03b1-SG), a dystrophin-associated glycoprotein that plays a key role in the maintenance of sarcolemma integrity in striated muscles. We report here on the development of a new <jats:italic>in vitro<\/jats:italic> high-throughput screening assay that allows the monitoring of the proper localization of the most prevalent mutant form of \u03b1-SG (R77C substitution). Using this assay, we screened a library of 2560 FDA-approved drugs and bioactive compounds and identified thiostrepton, a cyclic antibiotic, as a potential drug to repurpose for LGMD2D treatment. Characterization of the thiostrepton effect revealed a positive impact on R77C-\u03b1-SG and other missense mutant protein localization (R34H, I124T, V247M) in fibroblasts overexpressing these proteins. Finally, further investigations of the molecular mechanisms of action of the compound revealed an inhibition of the chymotrypsin-like activity of the proteasome 24\u2009h after thiostrepton treatment and a synergistic effect with bortezomib, an FDA-approved proteasome inhibitor. This study reports on the first <jats:italic>in vitro<\/jats:italic> model for LGMD2D that is compatible with high-throughput screening and proposes a new therapeutic option for LGMD2D caused by missense mutations of \u03b1-SG.<\/jats:p>","DOI":"10.1038\/s41598-019-43399-w","type":"journal-article","created":{"date-parts":[[2019,5,7]],"date-time":"2019-05-07T00:21:22Z","timestamp":1557188482000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Identification of thiostrepton as a pharmacological approach to rescue misfolded alpha-sarcoglycan mutant proteins from degradation"],"prefix":"10.1038","volume":"9","author":[{"given":"Lucile","family":"Hoch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara F.","family":"Henriques","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celine","family":"Bruge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justine","family":"Marsolier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manon","family":"Benabides","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Bourg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johana","family":"Tournois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gurvan","family":"Mah\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lise","family":"Morizur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margot","family":"Jarrige","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Bigot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Richard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3374-6274","authenticated-orcid":false,"given":"Xavier","family":"Nissan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,5,6]]},"reference":[{"issue":"2","key":"43399_CR1","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1002\/mus.26077","volume":"58","author":"Teerin Liewluck","year":"2018","unstructured":"Liewluck, T. & Milone, M. Untangling the complexity of limb-girdle muscular dystrophies. Muscle & nerve, https:\/\/doi.org\/10.1002\/mus.26077 (2018).","journal-title":"Muscle & Nerve"},{"key":"43399_CR2","doi-asserted-by":"publisher","first-page":"744","DOI":"10.2741\/4418","volume":"21","author":"H Tarakci","year":"2016","unstructured":"Tarakci, H. & Berger, J. The sarcoglycan complex in skeletal muscle. Frontiers in bioscience 21, 744\u2013756 (2016).","journal-title":"Frontiers in bioscience"},{"key":"43399_CR3","doi-asserted-by":"publisher","first-page":"e28","DOI":"10.1017\/S1462399409001203","volume":"11","author":"D Sandona","year":"2009","unstructured":"Sandona, D. & Betto, R. Sarcoglycanopathies: molecular pathogenesis and therapeutic prospects. Expert reviews in molecular medicine 11, e28, https:\/\/doi.org\/10.1017\/S1462399409001203 (2009).","journal-title":"Expert reviews in molecular medicine"},{"key":"43399_CR4","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/0092-8674(94)90527-4","volume":"78","author":"SL Roberds","year":"1994","unstructured":"Roberds, S. L. et al. Missense mutations in the adhalin gene linked to autosomal recessive muscular dystrophy. Cell 78, 625\u2013633 (1994).","journal-title":"Cell"},{"key":"43399_CR5","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1038\/ng1195-257","volume":"11","author":"LE Lim","year":"1995","unstructured":"Lim, L. E. et al. Beta-sarcoglycan: characterization and role in limb-girdle muscular dystrophy linked to 4q12. Nature genetics 11, 257\u2013265, https:\/\/doi.org\/10.1038\/ng1195-257 (1995).","journal-title":"Nature genetics"},{"key":"43399_CR6","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1038\/ng1195-266","volume":"11","author":"CG Bonnemann","year":"1995","unstructured":"Bonnemann, C. G. et al. Beta-sarcoglycan (A3b) mutations cause autosomal recessive muscular dystrophy with loss of the sarcoglycan complex. Nature genetics 11, 266\u2013273, https:\/\/doi.org\/10.1038\/ng1195-266 (1995).","journal-title":"Nature genetics"},{"key":"43399_CR7","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1126\/science.270.5237.819","volume":"270","author":"S Noguchi","year":"1995","unstructured":"Noguchi, S. et al. Mutations in the dystrophin-associated protein gamma-sarcoglycan in chromosome 13 muscular dystrophy. Science 270, 819\u2013822 (1995).","journal-title":"Science"},{"key":"43399_CR8","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/ng1096-195","volume":"14","author":"V Nigro","year":"1996","unstructured":"Nigro, V. et al. Autosomal recessive limb-girdle muscular dystrophy, LGMD2F, is caused by a mutation in the delta-sarcoglycan gene. Nature genetics 14, 195\u2013198, https:\/\/doi.org\/10.1038\/ng1096-195 (1996).","journal-title":"Nature genetics"},{"key":"43399_CR9","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1038\/nrneurol.2016.35","volume":"12","author":"R Thompson","year":"2016","unstructured":"Thompson, R. & Straub, V. Limb-girdle muscular dystrophies - international collaborations for translational research. Nature reviews. Neurology 12, 294\u2013309, https:\/\/doi.org\/10.1038\/nrneurol.2016.35 (2016).","journal-title":"Nature reviews. Neurology"},{"key":"43399_CR10","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1136\/jnnp-2017-316736","volume":"89","author":"G Tasca","year":"2018","unstructured":"Tasca, G. et al. MRI in sarcoglycanopathies: a large international cohort study. Journal of neurology, neurosurgery, and psychiatry 89, 72\u201377, https:\/\/doi.org\/10.1136\/jnnp-2017-316736 (2018).","journal-title":"Journal of neurology, neurosurgery, and psychiatry"},{"key":"43399_CR11","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1038\/ejhg.2008.9","volume":"16","author":"M Trabelsi","year":"2008","unstructured":"Trabelsi, M. et al. Revised spectrum of mutations in sarcoglycanopathies. European journal of human genetics: EJHG 16, 793\u2013803, https:\/\/doi.org\/10.1038\/ejhg.2008.9 (2008).","journal-title":"European journal of human genetics: EJHG"},{"key":"43399_CR12","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1136\/jmg.34.6.470","volume":"34","author":"A Carrie","year":"1997","unstructured":"Carrie, A. et al. Mutational diversity and hot spots in the alpha-sarcoglycan gene in autosomal recessive muscular dystrophy (LGMD2D). Journal of medical genetics 34, 470\u2013475 (1997).","journal-title":"Journal of medical genetics"},{"key":"43399_CR13","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1093\/hmg\/ddn029","volume":"17","author":"M Bartoli","year":"2008","unstructured":"Bartoli, M. et al. Mannosidase I inhibition rescues the human alpha-sarcoglycan R77C recurrent mutation. Human molecular genetics 17, 1214\u20131221, https:\/\/doi.org\/10.1093\/hmg\/ddn029 (2008).","journal-title":"Human molecular genetics"},{"key":"43399_CR14","doi-asserted-by":"publisher","first-page":"170","DOI":"10.2353\/ajpath.2008.071146","volume":"173","author":"S Gastaldello","year":"2008","unstructured":"Gastaldello, S. et al. Inhibition of proteasome activity promotes the correct localization of disease-causing alpha-sarcoglycan mutants in HEK-293 cells constitutively expressing beta-, gamma-, and delta-sarcoglycan. The American journal of pathology 173, 170\u2013181, https:\/\/doi.org\/10.2353\/ajpath.2008.071146 (2008).","journal-title":"The American journal of pathology"},{"key":"43399_CR15","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1002\/humu.21659","volume":"33","author":"T Soheili","year":"2012","unstructured":"Soheili, T. et al. Rescue of sarcoglycan mutations by inhibition of endoplasmic reticulum quality control is associated with minimal structural modifications. Human mutation 33, 429\u2013439, https:\/\/doi.org\/10.1002\/humu.21659 (2012).","journal-title":"Human mutation"},{"key":"43399_CR16","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1093\/hmg\/ddy013","volume":"27","author":"M Carotti","year":"2018","unstructured":"Carotti, M. et al. Repairing folding-defective alpha-sarcoglycan mutants by CFTR correctors, a potential therapy for limb-girdle muscular dystrophy 2D. Human molecular genetics 27, 969\u2013984, https:\/\/doi.org\/10.1093\/hmg\/ddy013 (2018).","journal-title":"Human molecular genetics"},{"key":"43399_CR17","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1002\/ajmg.a.38326","volume":"173","author":"W Sun","year":"2017","unstructured":"Sun, W., Zheng, W. & Simeonov, A. Drug discovery and development for rare genetic disorders. American journal of medical genetics. Part A 173, 2307\u20132322, https:\/\/doi.org\/10.1002\/ajmg.a.38326 (2017).","journal-title":"American journal of medical genetics. Part A"},{"key":"43399_CR18","doi-asserted-by":"publisher","first-page":"3746","DOI":"10.1093\/hmg\/ddu088","volume":"23","author":"E Bianchini","year":"2014","unstructured":"Bianchini, E., Fanin, M., Mamchaoui, K., Betto, R. & Sandona, D. Unveiling the degradative route of the V247M alpha-sarcoglycan mutant responsible for LGMD-2D. Human molecular genetics 23, 3746\u20133758, https:\/\/doi.org\/10.1093\/hmg\/ddu088 (2014).","journal-title":"Human molecular genetics"},{"key":"43399_CR19","doi-asserted-by":"publisher","first-page":"e39404","DOI":"10.1371\/journal.pone.0039404","volume":"7","author":"K Newick","year":"2012","unstructured":"Newick, K. et al. Peroxiredoxin 3 is a redox-dependent target of thiostrepton in malignant mesothelioma cells. PloS one 7, e39404, https:\/\/doi.org\/10.1371\/journal.pone.0039404 (2012).","journal-title":"PloS one"},{"key":"43399_CR20","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1111\/jcmm.12602","volume":"19","author":"C Sandu","year":"2015","unstructured":"Sandu, C. et al. Thiostrepton interacts covalently with Rpt subunits of the 19S proteasome and proteasome substrates. Journal of cellular and molecular medicine 19, 2181\u20132192, https:\/\/doi.org\/10.1111\/jcmm.12602 (2015).","journal-title":"Journal of cellular and molecular medicine"},{"key":"43399_CR21","doi-asserted-by":"publisher","first-page":"e5592","DOI":"10.1371\/journal.pone.0005592","volume":"4","author":"UG Bhat","year":"2009","unstructured":"Bhat, U. G., Halasi, M. & Gartel, A. L. Thiazole antibiotics target FoxM1 and induce apoptosis in human cancer cells. PloS one 4, e5592, https:\/\/doi.org\/10.1371\/journal.pone.0005592 (2009).","journal-title":"PloS one"},{"key":"43399_CR22","first-page":"5450","volume":"7","author":"L Jiang","year":"2014","unstructured":"Jiang, L., Wang, P., Chen, L. & Chen, H. Down-regulation of FoxM1 by thiostrepton or small interfering RNA inhibits proliferation, transformation ability and angiogenesis, and induces apoptosis of nasopharyngeal carcinoma cells. International journal of clinical and experimental pathology 7, 5450\u20135460 (2014).","journal-title":"International journal of clinical and experimental pathology"},{"issue":"2","key":"43399_CR23","doi-asserted-by":"publisher","first-page":"57","DOI":"10.3390\/ph11020057","volume":"11","author":"Jaswanth Yella","year":"2018","unstructured":"Yella, J. K., Yaddanapudi, S., Wang, Y. & Jegga, A. G. Changing Trends in Computational Drug Repositioning. Pharmaceuticals 11, https:\/\/doi.org\/10.3390\/ph11020057 (2018).","journal-title":"Pharmaceuticals"},{"key":"43399_CR24","first-page":"554","volume":"3","author":"R Donovick","year":"1955","unstructured":"Donovick, R., Pagano, J. F., Stout, H. A. & Weinstein, M. J. Thiostrepton, a new antibiotic. I. In vitro studies. Antibiotics annual 3, 554\u2013559 (1955).","journal-title":"In vitro studies. Antibiotics annual"},{"key":"43399_CR25","first-page":"560","volume":"3","author":"JD Dutcher","year":"1955","unstructured":"Dutcher, J. D. & Vandeputte, J. Thiostrepton, a new antibiotic. II. Isolation and chemical characterization. Antibiotics annual 3, 560\u2013561 (1955).","journal-title":"Antibiotics annual"},{"key":"43399_CR26","first-page":"562","volume":"3","author":"WP Jambor","year":"1955","unstructured":"Jambor, W. P., Steinberg, B. A. & Suydam, L. O. Thiostrepton, a new antibiotic. III. In vivo studies. Antibiotics annual 3, 562\u2013565 (1955).","journal-title":"Antibiotics annual"},{"key":"43399_CR27","doi-asserted-by":"publisher","first-page":"e6593","DOI":"10.1371\/journal.pone.0006593","volume":"4","author":"UG Bhat","year":"2009","unstructured":"Bhat, U. G., Halasi, M. & Gartel, A. L. FoxM1 is a general target for proteasome inhibitors. PloS one 4, e6593, https:\/\/doi.org\/10.1371\/journal.pone.0006593 (2009).","journal-title":"PloS one"},{"key":"43399_CR28","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.4161\/cc.7.12.6032","volume":"7","author":"UG Bhat","year":"2008","unstructured":"Bhat, U. G., Zipfel, P. A., Tyler, D. S. & Gartel, A. L. Novel anticancer compounds induce apoptosis in melanoma cells. Cell cycle 7, 1851\u20131855, https:\/\/doi.org\/10.4161\/cc.7.12.6032 (2008).","journal-title":"Cell cycle"},{"key":"43399_CR29","doi-asserted-by":"publisher","first-page":"e17110","DOI":"10.1371\/journal.pone.0017110","volume":"6","author":"B Pandit","year":"2011","unstructured":"Pandit, B. & Gartel, A. L. Thiazole antibiotic thiostrepton synergize with bortezomib to induce apoptosis in cancer cells. PloS one 6, e17110, https:\/\/doi.org\/10.1371\/journal.pone.0017110 (2011).","journal-title":"PloS one"},{"key":"43399_CR30","doi-asserted-by":"publisher","first-page":"3912","DOI":"10.4049\/jimmunol.1500194","volume":"195","author":"CY Lai","year":"2015","unstructured":"Lai, C. Y. et al. Identification of Thiostrepton as a Novel Inhibitor for Psoriasis-like Inflammation Induced by TLR7-9. Journal of immunology 195, 3912\u20133921, https:\/\/doi.org\/10.4049\/jimmunol.1500194 (2015).","journal-title":"Journal of immunology"},{"key":"43399_CR31","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1634\/theoncologist.8-6-508","volume":"8","author":"RC Kane","year":"2003","unstructured":"Kane, R. C., Bross, P. F., Farrell, A. T. & Pazdur, R. Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy. The oncologist 8, 508\u2013513 (2003).","journal-title":"The oncologist"},{"key":"43399_CR32","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1139\/cjpp-2017-0795","volume":"96","author":"V Sutariya","year":"2018","unstructured":"Sutariya, V. et al. Nanodrug delivery platform for glucocorticoid use in skeletal muscle injury. Canadian journal of physiology and pharmacology 96, 681\u2013689, https:\/\/doi.org\/10.1139\/cjpp-2017-0795 (2018).","journal-title":"Canadian journal of physiology and pharmacology"},{"key":"43399_CR33","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1016\/j.addr.2012.09.039","volume":"65","author":"X Chen","year":"2013","unstructured":"Chen, X., Zaro, J. L. & Shen, W. C. Fusion protein linkers: property, design and functionality. Advanced drug delivery reviews 65, 1357\u20131369, https:\/\/doi.org\/10.1016\/j.addr.2012.09.039 (2013).","journal-title":"Advanced drug delivery reviews"},{"key":"43399_CR34","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1089\/hum.2008.163","volume":"20","author":"S Chaouch","year":"2009","unstructured":"Chaouch, S. et al. Immortalized skin fibroblasts expressing conditional MyoD as a renewable and reliable source of converted human muscle cells to assess therapeutic strategies for muscular dystrophies: validation of an exon-skipping approach to restore dystrophin in Duchenne muscular dystrophy cells. Human gene therapy 20, 784\u2013790, https:\/\/doi.org\/10.1089\/hum.2008.163 (2009).","journal-title":"Human gene therapy"},{"key":"43399_CR35","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/j.cell.2006.07.024","volume":"126","author":"K Takahashi","year":"2006","unstructured":"Takahashi, K. & Yamanaka, S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126, 663\u2013676, https:\/\/doi.org\/10.1016\/j.cell.2006.07.024 (2006).","journal-title":"Cell"},{"key":"43399_CR36","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-14-128","volume":"14","author":"EY Chen","year":"2013","unstructured":"Chen, E. Y. et al. Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool. BMC bioinformatics 14, 128, https:\/\/doi.org\/10.1186\/1471-2105-14-128 (2013).","journal-title":"BMC bioinformatics"},{"key":"43399_CR37","doi-asserted-by":"publisher","first-page":"W90","DOI":"10.1093\/nar\/gkw377","volume":"44","author":"MV Kuleshov","year":"2016","unstructured":"Kuleshov, M. V. et al. Enrichr: a comprehensive gene set enrichment analysis web server 2016 update. Nucleic acids research 44, W90\u201397, https:\/\/doi.org\/10.1093\/nar\/gkw377 (2016).","journal-title":"Nucleic acids research"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-43399-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-43399-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-43399-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T09:17:07Z","timestamp":1671268627000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-43399-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,6]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["43399"],"URL":"https:\/\/doi.org\/10.1038\/s41598-019-43399-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,6]]},"assertion":[{"value":"19 October 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"6915"}}